Skip to content

English
Français

Careers
Contact Us

About DBV
- Overview
- Leadership
Our Pipeline
- Overview
- Clinical Trials
- VIASKIN^® peanut patch
- VIASKIN^® milk patch
- VIASKIN^® milk patch for EoE
- Expanded Access Program
Our Science
Investors
Newsroom
- Press Releases
- Media Kit

News

News

Select Year
Search News

Found 508 Results

Page 4 of 51« First «...2 345 6...10 20 30...»Last »

February 5, 2026

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026

January 16, 2026

DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing

January 12, 2026

Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

January 7, 2026

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

January 6, 2026

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

January 5, 2026

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

December 16, 2025

DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN^® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

December 2, 2025

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025

November 11, 2025

DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN^® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

November 4, 2025

DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Page 4 of 51« First «...2 345 6...10 20 30...»Last »

Investor Relations Contact

Jonathan Neely

+1 848-388-4584

jonathan.neely@dbv-technologies.com

Media Contact

Brett Whelan

+1 848-350-7622

brett.whelan@dbv-technologies.com

Subscribe to get the latest DBV press releases

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

Homepage
About DBV
Our Pipeline
Our Science
News
Investors
Careers
Contact Us

© 2026 DBV Technologies. All rights reserved.
Les traitements de DBV Technologies sont expérimentaux et ne sont pas approuvés par la FDA.

Terms of Use
Privacy Policy
Legal Notice
Cookies Policy

Scroll to Top